::::: Welcome to PowerPak C.E. (R) :::::

FACULTY

John A. Sunyecz, MD, FACOG
President, MenopauseRx, Inc.
Uniontown, PA;
Vice President, Laurel Highlands Ob/Gyn, P.C.
Hopwood, PA

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter	Reported Financial Relationship
John A. Sunyecz, MD	Clinical Investigator—Roche Speakers’ Bureau—GlaxoSmithKline, Roche, Ortho

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager	Reported Financial Relationship
Linda Graham, RN, BSN, BA	No real or apparent conflicts of interest to report.
Joseph Cupolo, MA, MS	No real or apparent conflicts of interest to report.

ACCREDITATION STATEMENTS

Pharmacy
acpe Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Program No.: 430-000-08-007-H01-P; 430-000-08-007-H01-T
Credits: 2.0 hours (0.20 ceu)

Published: May 1, 2008

Expires: May 31, 2010

ACCME Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Postgraduate Healthcare Education, LLC. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s).™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

Media: Monograph

Estimated time to complete activity:
Estimated time to complete this program and posttest is 90 to 120 minutes.

Exam processing inquiries and booklet orders to:
CE Customer Service Manager (800) 825-4696

Direct educational content inquiries to:
CE Director (800) 331-9396

PROCEDURE

Please complete the posttest questions and program evaluation online at: www.powerpak.com (a username and password are required to access your account). Upon passing the exam with a score of 70% or better, you can print out your statement of credit immediately. You can also view your test history at any time and print out duplicate statements from the Web site.

Release Date: May 1, 2008

Expiration Date: May 31, 2009

TARGET AUDIENCE

This activity has been designed to meet the educational needs of pharmacists, pharmacy technicians, and physicians, including primary care physicians, rheumatologists, endocrinologists, OB/GYNs, and other practitioners involved in the management of patients with osteoporosis.

STATEMENT OF NEED/PROGRAM OVERVIEW

This program has been developed to educate clinicians on the epidemiology of osteoporosis, and provide strategies for its management, including the use of calcium and vitamin D supplementation in combination with other therapies.

EDUCATIONAL OBJECTIVES

After completing this program, participants will be able to:

Review the signs, symptoms, risk factors, and diagnosis of osteoporosis;*
Describe the issues that may result in increased morbidity and mortality in patients with osteoporosis;*
Describe the non-pharmacological and pharmacological approaches for the prevention and management of osteoporosis, with emphasis on the need for calcium and vitamin D supplementation in conjunction with bisphosphonate therapy;*
List strategies for clinicians to make appropriate prevention/management recommendations, including patient education to educate and counsel patients

*Also applies to pharmacy technicians.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), Postgraduate Healthcare Education (PHE), and GlaxoSmithKline Consumer Healthcare do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, PHE, and GlaxoSmithKline Consumer Healthcare. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.